0VY.F I-MAB SPONS.ADS/1 -0001

Healthcare Biotechnology Frankfurt Exchange
0.7600 EUR
Close of Nov 11, 2026
0.7600 4.46
Market cap
EUR 88.2M
P/E
-
P/B
0.49x
ROE
-20.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 0VY.F undervalued?

Graham number

The Graham number of I-MAB SPONS.ADS/1 -0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

I-MAB SPONS.ADS/1 -0001 fundamental analysis

No fundamental analysis for I-MAB SPONS.ADS/1 -0001 yet.

I-MAB SPONS.ADS/1 -0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About I-MAB SPONS.ADS/1 -0001

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestina…

Full company profile